1 Medical School, The University of Jordan, Amman, Jordan.
2 Jordan University Hospital, Amman, Jordan.
3 Cell Therapy Center, The University of Jordan, Amman, Jordan.
4 Al-Basheer Hospital, Ministry of Health, Amman, Jordan.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and objective:
Very scanty reports from the middle east and north Africa (MENA) region
have been published on multiple myeloma (MM). Multiple myeloma registry
has been established at Jordan University Hospital (JUH) since 2009. In
this work we aim to review Multiple Myeloma registry with data from 113
patients who were diagnosed with MM at JUH and analyze their management
|Table 1. Demographic and laboratory data of all the patients with multiple myeloma.|
|Table 2. Mean and Median for Survival Time in months as per ISS stage, type of paraprotein and therapy.|
|Figure 1. Survival as per stage and the abnormal IgG and IgA paraprotein detected.|
|Figure 2. Survival (months) as per drug combination used.
|Figure 3. OS patients with aBMT.|
|Figure 4. PFS of aBMT patients.